Document:

Document

Exhibit 10.1
Draft | April 17, 2021

						
	

	Indemnification Agreement	
	
	dated as of [month] [day], [year]

	
	by and between

												
				
		Molecular Partners AG
	(the Company)

		Wagistrasse 14
8952 Schlieren
Switzerland
[e-mail]

		and	
				
		[Name of Director / Executive]
	(the Indemnitee and, together with the Company, the Parties and each, a Party)

		[address]
[e-mail]

				
		regarding the indemnification of the Indemnitee by the Company

Indemnification Agreement by and between Molecular Partners AG and [■]

Table of Contents
						
	1.    Definitions
	3
	2.    Indemnification
	4
	3.    Successful Defense and Partial Indemnification
	6
	4.    Indemnification Procedure
	6
	4.1    Notification and Indemnification Request
	6
	4.2    Advance of Expenses
	6
	4.3    Payment to Cover Losses
	7
	5.    Non-Exclusivity; Insurance; Subrogation
	7
	6.    Remedies of the Indemnitee
	8
	7.    Company's Right to Participate
	8
	8.    Term of the Agreement
	9
	9.    Data Protection
	9
	10.  General Provisions
	9
	10.1    No Right to Continued Service
	9
	10.2    Notices
	9
	10.3    Entire Agreement
	10
	10.4    Amendments and Waivers
	10
	10.5    No Assignment
	10
	10.6    Severability
	10
	10.7    Delivery by Electronic Transmission
	10
	11.  Governing Law and Jurisdiction
	11
	11.1    Governing Law
	11
	11.2    Jurisdiction
	11

2/12

Indemnification Agreement by and between Molecular Partners AG and [■]

Whereas
A.    The Company is a Swiss corporation registered with the commercial register of the Canton of Zurich under the company identification number CHE-112.115.136.
B.    The Indemnitee has been elected by the general meeting of shareholders of the Company as a member of the board of directors of the Company (the Board) and / or appointed by the Board as a member of the management board of the Company (the Management Board), as the case may be. The Indemnitee in his or her capacity as a member of the Board and / or the Management Board may be exposed to litigation and other risks arising out of or in connection with his or her service on the Board and / or the Management Board.
C.    The Company desires to attract and retain highly qualified individuals to serve on the Board and the Management Board. Therefore, the Company intends to indemnify the members of the Board and the Management Board in order to provide them with as much protection as permitted by applicable laws and regulations.
D.    The current articles of association of the Company (the Articles) provide that the Company shall be required to reimburse the members of the Board for all expenses incurred in the interests of the corporation.
E.    This Indemnification Agreement (the Agreement) shall not supersede but supplement the Articles, any resolution of the Board relating to indemnification of members of the Board and / or the Management Board and any D&O Insurance (as defined below; collectively, the Other Indemnification Documents). This Agreement shall not be deemed a substitute nor diminish or abrogate any rights of the Indemnitee under the Other Indemnification Documents.
Now, therefore, the Parties agree as follows:
1.    Definitions
Capitalized terms used in this Agreement shall have the meanings assigned to them in the body of this Agreement or hereinafter, as applicable:
						
	Business Day	means any day, other than a Saturday or a Sunday, on which the commercial banks in Zurich are open for business throughout the day.

	Expense	means any and all attorneys' fees, retainers, court and administrative costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs and printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses of the types customarily incurred in connection with investigating, defending, prosecuting, participating, settling, appealing, or being a witness in, a Proceeding (or preparing for any of the foregoing), in each case actually and reasonably incurred by the Indemnitee.

3/12

Indemnification Agreement by and between Molecular Partners AG and [■]

						
	Loss(es)	means all losses, damages, liabilities, judgments, fines, penalties, amounts due or paid in settlement (if such settlement has been approved by the Company whereby such approval shall not be unreasonably withheld) and Expenses, in each case actually and reasonably incurred by the Indemnitee.

	Proceeding	means any threatened, pending or completed action, suit, claim, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other proceeding, whether brought by or in the right of the Company or otherwise, whether civil, criminal, administrative or investigative, including appeals and petitions therefrom, except for one initiated by the Indemnitee to enforce his or her rights under this Agreement.

2.    Indemnification
(a)    Subject to the limitations set forth in this Agreement, the Company shall indemnify and hold harmless the Indemnitee if he or she was, is or is threatened to be made party to, or participant in, or is otherwise involved (including as a witness) in, any Proceeding, by reason of:
(i)    any actual or alleged acts, consents or omissions in connection with the execution of his or her duties, or alleged duties, as a member of the Board and / or the Management Board;
(ii)    the fact that he or she is or was a member of the Board and / or the Management Board;
(iii)    the fact that while serving as a member of the Board and / or the Management Board he or she is or was serving as a director, member of the executive management, employee or agent of any of the Company's subsidiaries;
(iv)    the fact that while serving as a member of the Board and / or the Management Board he or she is or was serving at the request of the Company as a director, member of the executive management, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise (each of the aforementioned individually, an Enterprise); 
from and against all Losses in connection with such Proceeding, in each case:
(1)    to the fullest extent permitted by the Swiss Code of Obligations (the CO), other applicable laws and regulations and the Articles, as may be amended from time to time; and
(2)    provided that the Indemnitee acted in good faith and in a manner which he or she reasonably believed to be in the best interest of the Company and/or the applicable subsidiary and/or Enterprise, as the case may be, and in addition, with respect to any criminal Proceeding, he or she had no reasonable cause 
4/12

Indemnification Agreement by and between Molecular Partners AG and [■]

to believe his or her conduct was unlawful. The termination of any Proceeding by judgment, order, (in or out of court) settlement or conviction, or upon a plea of no contest (nolo contendere) or its equivalent, shall not, of itself, create a presumption that the Indemnitee did not satisfy the foregoing applicable standard of conduct.
(b)    Notwithstanding any provision in this Agreement to the contrary, the Company shall not be obliged to indemnify the Indemnitee in connection with any Proceeding, and the Indemnitee shall repay any Expenses advanced by the Company:
(i)    in respect of any claim, issue or matter as to which the Indemnitee shall have (A) been adjudged in a final and non-appealable judgment or decree of a court, arbitral tribunal or governmental or administrative authority of competent jurisdiction to have committed an intentional or grossly negligent breach of his or her duties as a member of the Board and / or the Management Board under applicable laws and regulations, the Articles and the Company's Organizational Rules (Organisationsreglement) and other material internal policies, and / or the Indemnitee's mandate, service or employment, or (B) acknowledged an intentional or grossly negligent breach of his or her duties as a member of the Board and / or the Management Board under applicable laws and regulations, the Articles, the Company's internal regulations or policies and / or the Indemnitee's mandate, service, employment or other agreement in a written in or out of court or tribunal acknowledgment or settlement; or
(ii)    if such indemnification were prohibited by the CO or other applicable laws and regulations.
(c)    To the fullest extent permitted under the CO and other applicable laws and regulations, the Company waives, and will cause any of its subsidiaries to waive, any claims it may have against the Indemnitee for any loss, damage, costs or expenses incurred or sustained by the Company and / or any of its subsidiaries by reason of any acts, consents or omissions by the Indemnitee in connection with the execution of his or her duties as a member of the Board and / or the Management Board, unless any such loss, damage, costs or expenses is or are attributable to conduct (including omissions) constituting an intentional or grossly negligent breach of his or her duties as a member of the Board and / or the Management Board under applicable laws and regulations, the Articles, the Company's internal regulations or policies and / or the Indemnitee's mandate, service, employment or other agreement.
(d)    To the extent that the Indemnitee is, by reason of his or her capacity as a member of the Board and / or the Management Board, a witness or required attendee in any Proceeding, he or she shall be indemnified by the Company against all Expenses in connection therewith.
(e)    Any indemnification under this Agreement (unless ordered by a court or arbitral tribunal), other than the advance of Expenses pursuant to Section 4.2, will be made by the Company only upon a determination relating to a specific case that indemnification of the Indemnitee is proper in the circumstances because he or she has satisfied the applicable standard of conduct set forth in Section 2(a) and is not subject to the limitations set forth in Section 2(b).
5/12

Indemnification Agreement by and between Molecular Partners AG and [■]

3.    Successful Defense and Partial Indemnification
(a)    To the extent that the Indemnitee has been successful on the merits or otherwise, including the dismissal of an action without prejudice, in defense of any Proceeding pursuant to Section 2(a), or in defense of any claim, issue or matter therein, the Company shall, subject to the limitations set forth in this Agreement, indemnify the Indemnitee against all Expenses in connection therewith.
(b)    If the Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of any Expenses in connection with the investigation, defense, settlement or appeal of a Proceeding, but not for the total amount thereof, the Company shall nevertheless indemnify the Indemnitee for the portion thereof to which Indemnitee is entitled.
4.    Indemnification Procedure
4.1    Notification and Indemnification Request
(a)    The Indemnitee shall promptly notify the Company in writing upon being served with any claim, summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification of Losses and / or advancement of Expenses covered hereunder (any such proceeding (whether notified by the Indemnitee or otherwise known to the Company), a Relevant Proceeding). The failure of the Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement, unless and only to the extent that such failure actually and materially prejudices the Company.
(b)    In order to obtain indemnification of Losses and / or an advance of Expenses under this Agreement, the Indemnitee shall submit to the Company a written request, including such documentation and information as is reasonably available to the Indemnitee and is reasonably necessary to determine whether and to what extent the Indemnitee is entitled to such indemnification or advance, including the person(s) making (or threatening to make) the respective Proceeding, the circumstances leading to such a Proceeding, the cause of action for the Proceeding and the possible costs associated with the Proceeding.
4.2    Advance of Expenses
(a)    Without prejudice to the entitlement of the Indemnitee to indemnification of Losses under this Agreement, the Company shall advance to the Indemnitee all Expenses in connection with (i) any Proceeding pursuant to Section 2(a), (ii) any proceeding or action reasonably brought by the Indemnitee to seek recovery under the D&O Insurance (as defined below) and (iii) any proceeding or action reasonably brought by the Indemnitee to enforce this Agreement pursuant to Section 6, in each case within 20 (twenty) Business Days after receipt by the Company of a statement pursuant to Section 4.1 from the Indemnitee requesting such advance from time to time and 
6/12

Indemnification Agreement by and between Molecular Partners AG and [■]

evidencing such Expenses, whether prior to or after the final disposition of such proceeding.
(b)    The Indemnitee shall repay any Expenses advanced by the Company if it is ultimately determined that the Indemnitee is not entitled to be indemnified against such Expenses.
4.3    Payment to Cover Losses
Notwithstanding any right for repayment the Company may have under this Agreement and subject to the determination by the Company pursuant to Section 2(e), any payment to the Indemnitee to cover Losses pursuant to the indemnification entitlement according to Section 2 shall be made no later than 20 (twenty) Business Days after the Company has received the written request of the Indemnitee pursuant to Section 4.1.
5.    Non-Exclusivity; Insurance; Subrogation
(a)    The rights of indemnification of Losses and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of, and shall not limit, any other rights to which the Indemnitee may at any time be entitled under applicable law, the Articles, a resolution of the general meeting of shareholders of the Company or the Board, the D&O Insurance (as defined below), the Other Indemnification Documents, any other agreement or otherwise.
(b)    To the extent that the Company maintains an insurance policy or policies providing liability insurance for members of the Board and / or the Management Board (the D&O Insurance), the Indemnitee shall be covered by such D&O Insurance in accordance with its terms to the maximum extent of the coverage available for any such members of the Board and / or the Management Board under such D&O Insurance.
(c)    If, at the time the Company receives notice of a Relevant Proceeding by the Indemnitee, the Company maintains a D&O Insurance and without limitation to the Company's obligations under this Agreement, the Company shall give prompt notice of such Proceeding to the insurance company providing the D&O Insurance and take all necessary or desirable actions to cause such insurance company to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms and conditions of the D&O Insurance, provided that this obligation shall not relieve the Indemnitee from any of his or her obligations under the D&O Insurance.
(d)    The Company shall indemnify the Indemnitee against all Expenses in connection with any proceeding or action reasonably brought by the Indemnitee to seek recovery under the D&O Insurance.
(e)    The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that the Indemnitee is entitled to receive such payment under the D&O Insurance or has otherwise received such payment under any insurance policy, contract, agreement or otherwise.
7/12

Indemnification Agreement by and between Molecular Partners AG and [■]

(f)    In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of the Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including the execution of such documents necessary to enable the Company effectively to bring suit to enforce such rights.
6.    Remedies of the Indemnitee
If the Indemnitee initiates any action, suit, claim or any other proceeding to enforce his or her rights under this Agreement, the Indemnitee shall be entitled to recover from the Company, and shall be indemnified by the Company against, any and all Expenses in connection with such proceeding; provided, however, that if the competent court determines that any of the material assertions made by the Indemnitee in such proceeding was not made in good faith or was frivolous or if the final and non-appealable judgment or decree of a court confirms the Company's decision that the Indemnitee is not entitled to recover from the Company, then the Expenses in connection with such proceeding shall be borne by the Indemnitee, and the Indemnitee shall repay to the Company any advance payments. If it is determined in such proceeding that the Indemnitee is entitled to receive part but not all of the indemnification or advance of Expenses sought, the Expenses in connection with such proceeding shall be appropriately prorated and the Indemnitee shall repay to the Company the respective portion of the advance payments.
7.    Company's Right to Participate
(a)    The Company shall be entitled to participate in any Relevant Proceeding at its own expense and to assume the defense of any Relevant Proceeding.
(b)    After notice from the Company to the Indemnitee of its election to assume the defense of a Relevant Proceeding, the Company shall not be liable to the Indemnitee under this Agreement for any Expenses subsequently incurred by the Indemnitee in connection with the defense of such Relevant Proceeding other than reasonable costs of investigation or as otherwise provided below. The Indemnitee shall have the right to employ his or her own counsel in such Relevant Proceeding, but the fees and expenses of such counsel incurred after notice from the Company of its assumption of the defense thereof shall be at the sole expense of the Indemnitee unless (i) the Indemnitee's counsel shall have reasonably concluded that there may be a conflict of interest between the Company and the Indemnitee in the conduct of the defense of such Relevant Proceeding or (ii) the Company shall not in fact have employed counsel to assume the defense of such Relevant Proceeding, in each of which cases the reasonable fees and expenses of the Indemnitee's counsel shall be at the expense of the Company.
(c)    The Company shall not be liable to indemnify the Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding effected without its written consent. The Indemnitee shall not make any admission without the Company's written consent unless the Indemnitee shall have determined to undertake his or her own defense in 
8/12

Indemnification Agreement by and between Molecular Partners AG and [■]

such matter and has waived his rights and benefits under this Agreement. The Company shall not settle any Proceeding in any manner that would impose any penalty or limitation on or disclosure obligation with respect to the Indemnitee without the Indemnitee's written consent. Neither the Company nor the Indemnitee will unreasonably withhold the consent to any proposed settlement.
(d)    Irrespective of which Party to this Agreement participates in a Proceeding, both the Company and the Indemnitee undertake to cooperate and to provide each other with all information reasonably necessary in order to defend any claims against the Indemnitee.
8.    Term of the Agreement
(a)    This Agreement shall enter into force on the day on which the U.S. Securities and Exchange Commission first declares effective the Company's registration statement on Form F-1.
(b)    This Agreement shall be in full force and effect for so long as the Indemnitee may have any liability or potential liability by virtue of serving or having served as a member of the Board and / or the Management Board, including, without limitation, the final termination of all pending Proceedings in respect of which the Indemnitee is entitled to indemnification of Losses or advance of Expenses hereunder and of any Proceeding commenced by the Indemnitee pursuant to Section 6. The Indemnitee's rights under this Agreement shall continue after the Indemnitee has ceased to be a member of the Board and / or the Management Board.
9.    Data Protection
The Indemnitee agrees that the Company may forward to its subsidiaries and affiliated entities or any other third party (including, but not limited to, insurance companies, service providers, courts and public authorities) in Switzerland and / or abroad the Indemnitee's data for processing purposes.
10.    General Provisions
10.1    No Right to Continued Service
Nothing contained in this Agreement shall be construed as giving the Indemnitee any right to be retained in the employ of the Company or any of its subsidiaries or affiliated entities. No provision in this Agreement shall confer upon the Indemnitee any right to continue to serve the Company in the capacity in effect at the time this Agreement was executed or shall affect the right of the Company to terminate the Indemnitee's contractual relationship with the Company in accordance with such contractual relationship and applicable law.
10.2    Notices
All notices or other communications to be given under or in connection with this Agreement shall be made in writing and in English, and shall be delivered by hand, by 
9/12

Indemnification Agreement by and between Molecular Partners AG and [■]

registered, certified or express mail (return receipt requested), courier or by electronic transmission in .pdf format or similar format to the addresses noted on the cover page or any substitute address as a Party may notify to the other in accordance with the above by not less than five Business Days' notice.
10.3    Entire Agreement
With the exception of the Other Indemnification Documents, this Agreement constitutes the entire agreement and understanding among the Parties with respect to the subject matter hereof, and shall supersede all prior oral and written agreements or understandings of the Parties relating hereto other than any contained in the Other Indemnification Documents.
10.4    Amendments and Waivers
This Agreement (including this Section 10.4) may only be modified or amended by a document signed by both Parties. Any provision contained in this Agreement may only be waived by a document signed by the Party waiving such provision.
10.5    No Assignment
The Parties shall not assign this Agreement or any rights or obligations hereunder to any third party without the prior written consent of the other Party; provided, however, that the Company may assign this Agreement or any of its respective rights and obligations hereunder to any of its subsidiaries or affiliated entities without the prior written consent of the Indemnitee. This Agreement shall inure to the benefit of and be binding upon the Parties, and their respective successors, heirs, executors, administrators, and permitted assigns.
10.6    Severability
Should any part or provision of this Agreement be held to be invalid or unenforceable by any competent arbitral tribunal, court, governmental or administrative authority having jurisdiction, the other provisions of this Agreement shall nonetheless remain valid. In this case, the Parties shall negotiate in good faith a substitute provision that best reflects the economic intentions of the Parties without being unenforceable, and shall execute all agreements and documents required in this connection.
10.7    Delivery by Electronic Transmission
This Agreement and any other document relating to this Agreement, and any amendments hereto or thereto, to the extent signed and delivered by means of a facsimile machine, electronic signature or e-signature (irrespective of whether the relevant electronic signature or e-signature has been issued by a provider recognized or accredited under applicable law or not) or other electronic transmission (e.g., e-mail delivery in .pdf format or similar format), shall be treated in all manner and respects as an original contract and shall be considered to have the same binding legal effects as if it were the original signed version thereof delivered in person.
10/12

Indemnification Agreement by and between Molecular Partners AG and [■]

11.    Governing Law and Jurisdiction
11.1    Governing Law
This Agreement and any claim, controversy or dispute arising out of or related to this Agreement, whether arising in contract, tort or otherwise, shall be governed by and construed in accordance with the substantive laws of Switzerland without giving effect to any choice of law or conflict of law provision or rule that would result in the application of the laws of any jurisdiction other than Switzerland.
11.2    Jurisdiction
The exclusive place of jurisdiction for any dispute, claim or controversy arising under, out of or in connection with or related to this Agreement (or subsequent amendments thereof), including, without limitation, disputes, claims or controversies regarding its existence, validity, interpretation, performance, breach or termination, shall be Schlieren, Canton of Zurich, Switzerland.

[Signatures on next page]

11/12

Indemnification Agreement by and between Molecular Partners AG and [■]

Executed as of the date written on the cover page to this Agreement.
									
	Molecular Partners AG		
			
	Name:
Function:
		Name:
Function:

			
	The Indemnitee		
			
	Name:
Function:
		

12/12Document

Exhibit 10.2
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

LICENSE AGREEMENT
This agreement (“Agreement”) is made by and between
The University of Zurich
Ramistrasse 71 CH-8006 Zurich (Switzerland)
(“UNIVERSITY”)
And
Molecular Partners AG
c/o Patrik Forrer
Dept. of Biochemistry
University of Zurich
Winterthurerstr. 190
CH-8057 Zurich (Switzerland)
(“LICENSEE”)
This Agreement is effective on November 17, 2004 (“Effective Date”).
RECITALS
WHEREAS, UNIVERSITY is owner of Patent Rights as defined below on an invention in the field of collections of (poly)peptides/proteins based on repeat modules (“Invention”);
WHEREAS, UNIVERSITY is desirous that the Invention be developed and utilized to the fullest possible extent so that its benefits can be enjoyed by the general public;
WHEREAS, LICENSEE wishes to obtain, and UNIVERSITY is willing to grant, an exclusive license to the Patent Rights on the terms and conditions set out below.
NOW, THEREFORE, the parties agree:
ARTICLE 1 DEFINITIONS
The terms, as defined herein, shall have the same meanings in both their singular and plural forms.
1.1“Affiliate” means any corporation or other business entity in which LICENSEE owns or controls, directly or indirectly, at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors, or in which LICENSEE is owned or controlled directly or indirectly by at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors.
1.2“Sublicensee” means a third party to whom LICENSEE grants a sublicense of certain rights granted to LICENSEE under this Agreement.

1.3“Field” means therapeutic use (“Field A”), in vitro diagnostic use (“Field B”), use as research reagent (“Field C”) and any other uses.
1.4“Territory” means world-wide.
1.5“Term” means the period of time beginning on the Effective Date and ending on the expiration date of the longest-lived Patent Rights.
1.6“Patent Rights” means any of the following: the patent applications listed in Annex A disclosing and claiming the Invention and continuing applications thereof including divisions, substitutions, and continuations-in-part (but only to extent the claims thereof are enabled by disclosure of the parent application); any patents issuing on said applications including reissues, reexaminations and extensions; and any corresponding applications, patents and extensions in other countries.
1.7“Licensed Method” means any method that is covered by Patent Rights the use of which would constitute, but for the license granted to LICENSEE under this Agreement, an infringement of any pending or issued and unexpired claim within Patent Rights.
1.8“Licensed Product” means any composition, product or service that is covered by the claims of Patent Rights, or that is developed or produced by the Licensed Method, or the manufacture, use, sale, offer for sale, or importation of which would constitute, but for the license granted to LICENSEE by UNIVERSITY herein, an infringement of any pending or issued and unexpired claim within the Patent Rights.
1.9“Net Sales” means the total of the gross invoice prices billed by or on behalf of LICENSEE or its Affiliates or its Sublicensees to third parties on sales of Licensed Products in bona fide arm’s length transactions, less the sum of the following actual and customary deductions where applicable and separately itemized on the invoice and actually paid or allowed: cash, trade, or quantity discounts; value added, sales or use taxes, and custom duties; transportation charges; or credits to customers because of rejections or returns. For purposes of calculating Net Sales, transfers to a Sublicensee or an Affiliate or a distributor of Licensed Product under this Agreement for (i) end use (but not resale) by the Sublicensee or Affiliate or distributor shall be treated as sales by LICENSEE at list price of LICENSEE, or (ii) resale by a Sublicensee or an Affiliate or a distributor shall be treated as sales at the list price of the Sublicensee or Affiliate or distributor. Non-monetary consideration shall not be accepted by LICENSEE, a Sublicensee, an Affiliate, or a distributor for any Licensed Products or Licensed Methods without the prior written consent of UNIVERSITY which consent shall not be unreasonably refused. For the avoidance of doubt Net Sales shall be calculated only once for the first sale of such Licensed Product by either LICENSEE, its Affiliates, or Sublicensees, as the case may be, to a third party. The initial sale of Licensed Product by LICENSEE, its Affiliates, or Sublicensees to a wholesaler shall be regarded as the first sale of the Licensed Product for the purpose of calculating Net Sales.
1.1“First Commercial Sale” means the initial transfer by or on behalf of LICENSEE or its Affiliates, Sublicensees or distributors of Licensed Product to a third party end user customer in exchange for cash in any country after all required marketing and pricing approvals have been granted, or otherwise permitted, by the authorities of such country.

ARTICLE 2 GRANTS
2.1License. Subject to the limitations set forth in this Agreement, UNIVERSITY hereby grants to LICENSEE, and LICENSEE hereby accepts, a license under Patent Rights to make, use, sell, offer for sale, and import Licensed Products and to practice Licensed Methods, in the Field within the Territory and during the Term The license granted herein is exclusive for Patent Rights and UNIVERSITY shall not grant to third parties a further license under Patent Rights in the Field, within the Territory and during the Term.
2.2Sublicense.
(a)The license granted in Paragraph 2.1 includes the right of LICENSEE to grant sublicenses to third parties during the Term. The terms and conditions of any sublicense shall be in accordance with sound and reasonable business practices and any fees charged shall not be unreasonable for comparable rights.
(b)With respect to any sublicense granted pursuant to Paragraph 2.2(a), LICENSEE shall:
(1)not receive, or agree to receive, anything of value in lieu of cash as considerations from a third party under a sublicense granted pursuant to Paragraph 2.2(a) without the express written consent of UNIVERSITY which consent shall not be unreasonably refused;
(2)to the extent applicable, include all of the rights of and obligations due to UNIVERSITY and contained in this Agreement;
(3)promptly provide UNIVERSITY with a copy of each sublicense issued; and
(4)collect payment of all payments due, directly or indirectly, to UNIVERSITY from Sublicensees and summarize and deliver all reports due, directly or indirectly, to UNIVERSITY from Sublicensees.
(c)Upon termination of this Agreement for any reason, UNIVERSITY, at its sole discretion, shall determine whether LICENSEE shall cancel or assign to UNIVERSITY any and all sublicenses.
2.3Reservation of Rights. UNIVERSITY reserves the right to use the Invention and Patent Rights for educational and research purposes free of charge.
2.4Material Transfer. LICENSEE shall have the right to receive samples of biological material that is relevant to practice the granted rights which is in possession of UNIVERSITY and to which no third parties can claim any rights.
ARTICLE 3 CONSIDERATIONS
3.1Fees and Royalties. In consideration of the license granted herein to LICENSEE under Patent Rights LICENSEE agrees to pay to UNIVERSITY:

(a)in recognition of LICENSEE being a startup business and partially in lieu of cash, a license issue fee in the form of [***] shares with a nominal value of CHF [***] of LICENSEE’s common stock representing [***]% of the LICENSEE’s total authorized equity capital of CHF [***]. The stock or if stocks are not issued physically a copy of the updated share register shall be delivered to UNIVERSITY within [***] of execution of this Agreement. In the event of a capital increase the UNIVERSITY’s equity position may be diluted, however such dilution shall in no event be greater than that of [***] and furthermore UNIVERSITY’s equity position shall not be diluted below [***]% of the total outstanding stock of LICENSEE until LICENSEE has accrued total funds of CHF [***] in form of equity capital. Shares issued to University shall provide for equal but proportionate rights and restrictions as the Founder’s shares. UNIVERSITY shall adhere to the COMPANY’s shareholders agreement and such other agreements as may be required to give effect to this paragraph. The Founders of the COMPANY are Patrick Amstutz, Hans Kaspar Binz, Patrik Forrer, Martin Alexander Kawe, Andreas Pluckthun, Michael Tobias Stumpp and Christian Zahnd.
(b)an earned royalty on Net Sales of Licensed Products by LICENSEE or an Affiliate
(i)of [***] on Net Sales of Licensed Products for uses in Field A; and 
(ii)of [***] on Net Sales of Licensed Products for uses in Field B; and 
(iii)of [***] on Net Sales of Licensed Products for uses in Field C; and 
(iv)earned royalty on Net Sales for other uses than set forth above will be negotiated between the parties in good faith before the First Commercial Sale of such Licensed Products
(c)on all sublicense fees received by LICENSEE from each Sublicensee that are not earned royalties:
-    [***] on fraction < [***] CHF for particular sublicense by particular Sublicensee
-    [***] on fraction>= [***] CHF for particular sublicense by particular Sublicensee
It is understood that payments from Sublicensees to LICENSEE dedicated for direct use for the financing of research or product development under a joint research or development agreement shall not be considered sublicense fees and no compensation for UNIVERSITY shall be due on such payments.
(d)(i)    on each and every sublicense royalty payment received by LICENSEE from its Sublicensees on sales of Licensed Product by Sublicensee for use in Field A or in Field B, royalties based on the following royalty rate as applied to Net Sales of particular Sublicensee:
•If LICENSEE is receiving a royalty of less than [***] on the Net Sales of Sublicensee:[***] of such royalty income
•If LICENSEE is receiving a royalty of [***] or more but less than [***] on the Net Sales of Sublicensee: [***] of such royalty income but minimally [***] on the Net Sales of Sublicensee

•If LICENSEE is receiving a royalty of [***] or more on the Net Sales of Sublicensee: [***] on the Net Sales of Sublicensee
(ii)[***] on each and every sublicense royalty payment received by LICENSEE from its Sublicensees on sales of Licensed Product by Sublicensee for use in Field C.
(iii)on sublicense royalty payment received by LICENSEE from its Sublicensees on sales of Licensed Product for uses other than set forth above: rate will be negotiated between the parties in good faith before the First Commercial Sale of such Licensed Products.
(e)It is agreed that for the [***] of this Agreement LICENSEE shall be exempted from paying royalties to UNIVERSITY on annual income of LICENSEE resulting from Net Sales, sublicense fees and sublicense royalty and which is totally less than CHF [***].
All fees and royalty payments specified in this Paragraph 3.1 shall be paid by LICENSEE pursuant to Paragraph 4.3.
3.2Due Diligence.
(a)LICENSEE shall:
(1)diligently proceed with the development, manufacture and sale of Licensed Products;
(2)upon market entry on a country-by-country basis, use its reasonable efforts to promote the sale of the Licensed Products in the Territory [***] during the term of this Agreement; and
(3)obtain all necessary governmental approvals for the manufacture, use and sale of Licensed Products.
(b)[***].
ARTICLE 4 REPORTS, RECORDS AND PAYMENTS
4.1Reports.
(a)Progress Reports.
(1)Beginning January 1, 2006 and ending on the date of First Commercial Sale of a Licensed Product in the United States and Europe, LICENSEE shall submit to UNIVERSITY annual progress reports covering LICENSEE’s (and each Affiliate’s and Sublicensee’s) activities to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such reports shall include a summary of work completed; summary of work in progress; current schedule of anticipated events or milestones; market plans for introduction of Licensed Products; and summary of resources spent in the reporting period.

(2)LICENSEE shall also report to UNIVERSITY, in its immediately subsequent progress report, the date of First Commercial Sale of a Licensed Product in each country.
(b)Royalty Reports. After the First Commercial Sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual royalty reports on or before [***] of each year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar quarter and shall show:
(1)the gross sales, deductions as provided in Paragraph 1.9, and Net Sales during the most recently completed calendar year and the royalties payable with respect thereto;
(2)the number of each type of Licensed Product sold;
(3)sublicense fees and royalties received during the most recently completed calendar year;
(4)the method used to calculate the royalties; and
(5)the exchange rates used.
If no sales of Licensed Products has been made and no sublicense revenues have been received by LICENSEE during any reporting period, LICENSEE shall so report.
4.2Records & Audits.
(a)LICENSEE shall keep, and shall require its Affiliates and Sublicensees to keep, accurate and correct records of all Licensed Products manufactured, used, and sold, and sublicense fees received under this Agreement. Such records shall be retained by LICENSEE for at least [***] years following a given reporting period.
(b)All records shall be available during normal business hours for inspection at the expense of UNIVERSITY by UNIVERSITY’s Internal Audit Department or by a public accountant selected by UNIVERSITY and in compliance with the other terms of this Agreement for the sole purpose of verifying reports and payments. Such inspector shall not disclose to UNIVERSITY any information other than information relating to the accuracy of reports and payments made under this Agreement or other compliance issues. In the event that any such inspection shows an underpayment in excess of [***] for any [***] period, then LICENSEE shall pay the cost of the audit as well as any additional sum that would have been payable to UNIVERSITY had LICENSEE reported correctly, plus an interest charge at a rate of [***] per year. Such interest shall be calculated from the date the correct payment was due to UNIVERSITY up to the date when such payment is actually made by LICENSEE.
For underpayment not in excess of [***] for any [***] period, LICENSEE shall pay the difference within [***] without interest charge or inspection costs.
4.3Payments.
(a)All fees due to UNIVERSITY shall be paid to:

[***]
(b)Royalty Payments.
(1)Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate.
(2)LICENSEE shall pay earned royalties annually on or before [***] of each calendar year. Each such payment shall be for earned royalties accrued within LICENSEE’s most recently completed calendar year.
(3)LICENSEE shall pay any withholding taxes on such royalties as required by law and provide to UNIVERSITY appropriate documentation of such tax payment. LICENSEE shall use reasonable efforts to: (i) avoid or minimize any such withholding; and (ii) take advantage of any double taxation treaty as may be available.
(4)In the event that any patent or patent claim within Patent Rights is held invalid in a final decision by a patent office from which no appeal or additional patent prosecution has been or can be taken, or by a court of competent jurisdiction and last resort and from which no appeal has or can be taken, all obligation to pay royalties based solely on that patent or claim or any claim patentably indistinct therefrom shall cease as of the date of such final decision. LICENSEE shall not, however, be relieved from paying any royalties that accrued before the date of such final decision, or that are based on another patent or claim not involved in such final decision.
(c)Late Payments. In the event royalty, reimbursement and/or fee payments are not received by UNIVERSITY when due, LICENSEE shall pay to UNIVERSITY interest charges at a rate of [***] per year. Such interest shall be calculated from the date payment was due until actually received by UNIVERSITY.
ARTICLE 5 PATENT MATTERS
5.1Patent Prosecution and Maintenance.
(a)LICENSEE, at its own expense, utilizing patent attorneys of its choice, shall be responsible for the filing, prosecution and maintenance of patent applications and patents within the Patent Rights. Any such filings shall be in the name of UNIVERSITY and LICENSEE shall be acting in the best interest of UNIVERSITY in filing, prosecuting and maintaining the Patent Rights.
(b)UNIVERSITY shall fully cooperate with LICENSEE in preparing, filing, prosecuting and maintaining any patent applications and patents in the Patent Rights. LICENSEE, or its patent counsel, shall consult with UNIVERSTY as to the preparation, filing, prosecution and maintenance of Patent Rights and provide UNIVERSITY with copies of all documentation relating to such prosecution and UNIVERSITY shall keep this documentation confidential.
(c)LICENSEE shall apply for an extension of the term of any patent in Patent Rights if appropriate under the US Drug Price Competition and Patent Term Restoration Act and/or European, Japanese and other foreign counterparts thereof. LICENSEE shall prepare all 

documents for such applications, and UNIVERSITY shall execute such documents and take any other additional action as LICENSEE reasonably requests in connection therewith.
(d)LICENSEE may elect to terminate its obligations with respect to any patent application or patent in Patent Rights upon [***] written notice to UNIVERSITY. UNIVERSITY, in its sole discretion and at its sole expense, may continue prosecution and maintenance of said application or patent, and LICENSEE shall then have no further license with respect thereto.
5.2Patent Infringement.
(a)If LICENSEE learns of any substantial infringement of Patent Rights, LICENSEE shall so inform UNIVERSITY and provide UNIVERSITY with reasonable evidence of the infringement. Neither party shall notify a third party of the infringement of Patent Rights without the consent of the other party. Both parties shall use reasonable efforts and cooperation to terminate infringement without litigation.
(b)LICENSEE may request UNIVERSITY to take legal action against such third party for the infringement of Patent Rights. Such request shall be made in writing and shall include reasonable evidence of such infringement and damages to LICENSEE. If the infringing activity has not abated [***] following LICENSEE’s request, UNIVERSITY shall elect to or not to commence suit on its own account. UNIVERSITY shall give notice of its election in writing to LICENSEE by the end of the [***] after receiving notice of such request from LICENSEE. LICENSEE may thereafter bring suit for patent infringement at its own expense, if and only if UNIVERSITY elects not to commence suit and the infringement occurred in a jurisdiction where LICENSEE has an exclusive license under this Agreement. If LICENSEE elects to bring suit, UNIVERSITY may join that suit at its own expense.
(c)Recoveries from actions brought pursuant to Paragraph 5.2(b) shall belong to the party bringing suit except that in the event that LICENSEE brings suit for infringement of Patent Rights and an acceptable settlement is entered into or monetary damages are awarded in a final non-appealable judgment, [***]. Legal actions brought jointly by UNIVERSITY and LICENSEE and fully participated in by both shall be at the joint expense of the parties and all recoveries shall be shared jointly by them in proportion to the share of expense paid by each party.
(d)Each party shall cooperate with the other in litigation proceedings at the expense of the party bringing suit. Litigation shall be controlled by the party bringing the suit, except that UNIVERSITY may be represented by counsel of its choice in any suit brought by LICENSEE.
5.3Patent Marking. LICENSEE shall mark all Licensed Products made, used or sold under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws.
ARTICLE 6 GOVERNMENTAL MATTERS
Governmental Approval or Registration. If this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency, LICENSEE shall assume all legal obligations to do so. LICENSEE shall notify UNIVERSITY if it becomes aware that this Agreement is subject to any government reporting or approval requirement. LICENSEE shall make all necessary filings and pay all costs including 

fees, penalties, and all other out-of-pocket costs associated with such reporting or approval process.
ARTICLE 7 TERMINATION OF THE AGREEMENT
7.1Termination by UNIVERSITY.
(a)If LICENSEE fails to perform or violates any term of this Agreement, then UNIVERSITY may give written notice of default (“Notice of Default”) to LICENSEE. If LICENSEE fails to cure the default within [***] of the Notice of Default, UNIVERSITY may terminate this Agreement and the license granted herein by a second written notice (“Notice of Termination”) to LICENSEE. If a Notice of Termination is sent to LICENSEE, this Agreement shall automatically terminate on the effective date of that notice. Termination shall not relieve LICENSEE of its obligation to pay any fees owed at the time of termination and shall not impair any accrued right of UNIVERSITY.
(b)UNIVERSITY shall have the right to terminate this Agreement by giving written notice, in the event of filing by LICENSEE of a petition of bankruptcy or insolvency or both, or in the event of an adjudication that LICENSEE is bankrupt or insolvent or both, or after filing by LICENSEE of any petition or pleading asking reorganization, readjustment or rearrangement of its business under any law relating to bankruptcy or insolvency, or upon or after appointment of a receiver for all or substantially all of the property of LICENSEE or upon or after the making of any assignment for the benefit of creditors or upon or after the institution of any proceedings for the liquidation or winding-up of LICENSEE’s business or for the termination of its corporate charter, and this Agreement shall terminate upon the date specified in such written notice.
7.2Termination by Licensee.
(a)LICENSEE shall have the right at any time and for any reason to terminate this Agreement upon a [***] written notice to UNIVERSITY. Said notice shall state LICENSEE’s reason for terminating this Agreement.
(b)Any termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation or liability accrued under this Agreement prior to termination or rescind any payment made to UNIVERSITY or action by LICENSEE prior to the time termination becomes effective. Termination shall not affect in any manner any rights of UNIVERSITY arising under this Agreement prior to termination.
7.3Survival on Termination. Upon expiration or termination of the Agreement, the obligations which by their nature are intended to survive expiration or termination of the Agreement shall survive.
7.4Disposition of Licensed Products on Hand. Upon termination of this Agreement, LICENSEE may dispose of all previously made or partially made Licensed Product within a period of [***] of the effective date of such termination provided that the sale of such Licensed Product by LICENSEE, its Sublicensees, or Affiliates shall be subject to the terms of this Agreement, including but not limited to the rendering of reports and payment of royalties required under this Agreement.

ARTICLE 8 LIMITED WARRANTY AND INDEMNIFICATION
8.1Limited Warranty.
(a)UNIVERSITY warrants that it has the lawful right to grant this license.
(b)The license granted herein is provided “AS IS” and without WARRANTY OF MERCHANTABILITY or WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE or any other warranty, express or implied. UNIVERSITY makes no representation or warranty that the Licensed Product, Licensed Method or the use of Patent Rights will not infringe any other patent or other proprietary rights.
(c)In no event shall UNIVERSITY be liable for any incidental, special or consequential damages resulting from exercise of the license granted herein or the use of the Invention, Licensed Product, or Licensed Method.
(d)Nothing in this Agreement shall be construed as:
(1)a warranty or representation by UNIVERSITY as to the validity or scope of any Patent Rights;
(2)a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or shall be free from infringement of patents of third parties;
(3)an obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in Paragraph 5.2 hereof.
8.2Indemnification.
(a)LICENSEE shall indemnify, hold harmless and defend UNIVERSITY, its officers, employees, and agents; and the inventors of the patents and patent applications in Patent Rights and their employers against any and all claims, suits, losses, damage, costs, fees, and expenses resulting from or arising out of exercise of this license or any sublicense. This indemnification shall include, but not be limited to, any product liability.
(b)LICENSEE, at its sole cost and expense, shall insure its activities in connection with the work under this Agreement and obtain, keep in force and maintain insurance or an equivalent program of self insurance.
(c)UNIVERSITY shall notify LICENSEE in writing of any claim or suit brought against UNIVERSITY in respect of which UNIVERSITY intends to invoke the provisions of this Article. LICENSEE shall keep UNIVERSITY informed on a current basis of its defense of any claims under this Article.
ARTICLE 9 USE OF NAMES AND TRADEMARKS
Nothing contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing). 

Notwithstanding the foregoing, each party may state orally or in writing, including press releases, the fact that the licence has been granted by University and that COMPANY is commercializing Patent Rights.
ARTICLE 10 MISCELLANEOUS PROVISIONS
10.1Correspondence. Any notice required to be given to either party under this Agreement shall be deemed to have been properly given and effective:
(a)[***] if delivered in person, or
(b)[***] after mailing if mailed by registered mail, postage paid, to the respective addresses given below, or to such other address as is designated by written notice given to the other party.
If sent to LICENSEE:
Molecular Partners AG, c/o Dept. of Biochemistry, University of Zurich, Winterthurerstr. 190, CH-8057 Zurich (SWITZERLAND)
Attention: [***] 
If sent to UNIVERSITY:
University of Zurich, c/o Unitectra, Technology Transfer Office; Ref. UZ- 01/103; Mohrlistrasse 23; CH-8006 Zurich (SWITZERLAND)
10.2Assignability. UNIVERSITY and LICENSEE each agree that their rights and obligations under this Agreement may not be transferred or assigned to a third party without the prior written consent of the other party thereto.
10.3No Waiver. No waiver by either party of any breach or default of any covenant or agreement set forth in this Agreement shall be deemed a waiver as to any subsequent and/or similar breach or default.
10.4Governing Laws. THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF SWITZERLAND. For any and all disputes arising from this Agreement, the Commercial Court of the Canton of Zurich shall have exclusive jurisdiction, subject to the appeal to the Swiss Supreme Court.
10.5Force Majeure. A party to this Agreement may be excused from any performance required herein if such performance is rendered impossible or unfeasible due to any catastrophe or other major event beyond its reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the non-performing party’s obligations herein shall resume.
10.6Headings. The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.

10.7Entire Agreement. This Agreement embodies the entire understanding of the parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof.
10.8Amendments. No amendment or modification of this Agreement shall be valid or binding on the parties unless made in writing and signed on behalf of each party.
10.9Severability. Should some or several provisions of this Agreement be ineffective or invalid, or should there be an omission in this Agreement, the effectiveness, respectively the validity of the remaining provisions shall not be affected thereby. An ineffective, respectively, invalid provision shall be replaced by the interpretation of the agreement which comes nearest to the economic meaning and the envisaged economic purpose of the ineffective respectively, invalid provision. The same applies in the case of a contractual gap.
*****************

IN WITNESS WHEREOF, both UNIVERSITY and LICENSEE have executed this Agreement, in duplicate originals, by their respective and duly authorized officers on the day and year first above written.
												
	UNIVERSITY
		
				
	Date: 			
	By: 	Peter Bless
		(Signature)
		Director of Administration
		
				
	Date:			
	By:	Prof. Alexander Borbely
		(Signature)
		Vice President for Research
		
				
	LICENSEE
		
				
	Date:			
	By:			(Signature)
				
				
	Date:			
	By:			(Signature)

Annex A
List of Patent Rights
[***]

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Amendment No. 1 dated November 15, 2005, to the License Agreement
between
The University of Zurich, Rämistrasse 71, CH-8006 Zürich (“UNIVERSITY”)
and
Molecular Partners AG, c/o Dept. of Biochemistry, University of Zurich, Winterthurerstr. 190.
CH-8057 Zürich (“LICENSEE”).
WHEREAS
a.    UNIVERSITY and LICENSEE have entered into a License Agreement, effective November 17, 2004, on “collections of (poly)peptides/proteins based on repeat modules (the “License Agreement”);
b.    LICENSEE wishes to license further patent rights owned by UNIVERSITY and UNIVERSITY agrees to license these patent rights to LICENSEE at the terms and conditions of the License Agreement; it is understood that the fees and royalties due for commercial use of such further patent rights are not cumulative with those of the License Agreement;
c.    The parties wish to amend the License Agreement accordingly.
NOW, IT IS AGREED AS FOLLOWS:
1.    Annex 1 of the License Agreement (“List of Patent Rights”) shall be amended as follows:
[***]
2.    All terms and conditions of the License Agreement shall remain in full force and effect.
3.    This Amendment shall be effective retroactively as of July 8, 2005.
* * * * * * * *
Amendment 1
Page 15 of 35

												
	For LICENSEE
		
				
	Date:			
				
	By:			
		(Printed Name and Title/Position)
		(Signature)
				
	Date:			
				
	By:			
		(Printed Name and Title/Position)
		(Signature)
				
	For UNIVERSITY
		
				
	Date:			
				
	By:			
				(Signature)
	Date:			
				
	By:			
				(Signature)

Amendment 1
Page 16 of 35

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Amendment No. 2 dated November 15, 2005, to the License Agreement
between
The University of Zurich, Rämistrasse 71, CH-8005 Zürich (“UNIVERSITY”)
and
Molecular Partners AG, c/o Dept of Biochemistry, University of Zurich, Winterthurerstr. 190.
CH-8057 Zürich (“LICENSEE”).
WHEREAS
a.    UNIVERSITY and LICENSEE have entered into a License Agreement, effective November 17, 2004, on “collections of (poly)peptides/proteins based on repeat modules (the “License Agreement”);
b.    The parties wish to amend the License Agreement in order to specify Art. 2.4 of the License Agreement on the transfer of biological material that is relevant to practice the granted rights from UNIVERSITY to LICENSEE particularly in regard to biological material which forms the basis of libraries.
NOW, IT IS AGREED AS FOLLOWS:
1.    Definitions:
„Original Library Material” shall mean the following biological materials:
[***]
[***]
[***]
[***]
“MATERIAL” shall mean Original Library Material and Progeny and Unmodified Derivatives thereof.
“Progeny” shall mean unmodified descendant from the MATERIAL, such as virus from virus, cell from cell, or organism from organism.
“Unmodified Derivatives” shall mean substances created by LICENSEE which solely constitute an unmodified functional subunit of the Original Library Material or a product expressed by the Original Library Material.
“Modifications” shall mean combinatorial DNA libraries created by LICENSEE which contain/incorporate the MATERIAL. It is agreed that any preparation of designed ankyrin repeat protein (DARPin) libraries by LICENSEE, which use one or more of the MATERIAL shall be considered to be Modifications.
“Binders” shall mean molecules with specific binding capacity isolated from above mentioned DARPin libraries
Amendment 2
Page 17 of 35

“Licensed Field of Use” shall mean therapeutic use, diagnostic use and biotechnological use.
2.    UNIVERSITY hereby grants to LICENSEE a worldwide, exclusive license to commercially exploit the MATERIAL, Modifications and Binders in the Licensed Field of Use.
3.    (a)  UNIVERSITY retains ownership of the MATERIAL.
(b)  Modifications and all subsequent libraries prepared by LICENSEE or UNIVERSITY based on Modifications shall be jointly owned by LICENSEE and UNIVERSITY.
(c)  Binders prepared from Modifications shall be owned by the party, which isolated such Binders.
4.    (a)  In consideration of the grant in Paragraph 2 above, LICENSEE hereby agrees that the financial terms set forth in Art. 3 of the License Agreement shall apply to any commercial use or sale of the MATERIAL, Modifications or Binders that fall under the definition of Licensed Product as set forth in the License Agreement. The fees and royalties due for the commercial use of such MATERIAL, Modifications or Binders are not cumulative with those of the License Agreement.
(b)  For any MATERIAL, Modifications or Binders which do not or not anymore fall under the definition of Licensed Product as set forth in the License Agreement: LICENSEE shall pay a reduced rate of [***] of what would be due to UNIVERSITY if such MATERIAL, Modification or Binder would constitute a Licensed Product. Payments under this Paragraph 4(b) shall only be due for the [***] after execution of this Amendment.
5.    Any MATERIAL delivered pursuant to this Amendment is understood to be experimental in nature and may have hazardous properties. UNIVERSITY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.
6.    Any Modifications delivered pursuant to this Amendment is understood to be experimental in nature and may have hazardous properties. LICENSEE MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.
7.    Except to the extent prohibited by law, LICENSEE assumes all liability for damages that may arise from its use, storage or disposal of the MATERIAL. UNIVERSITY will not be liable to LICENSEE for any loss, claim or demand made by LICENSEE, or made against LICENSEE by any other party, due to or arising from the use of the MATERIAL by LICENSEE.
8.    Except to the extent prohibited by law, UNIVERSITY assumes all liability for damages that may arise from its use, storage or disposal of the Modifications. LICENSEE will not be liable to UNIVERSITY for any loss, claim or demand made by UNIVERSITY, or made against UNIVERSITY by any other party, due to or arising from the use of the Modifications by UNIVERSITY.
9.    For the use of MATERIAL and Modifications the parties agree to provide appropriate
acknowledgment of the source of the MATERIAL or Modifications in all publications.
10.    LICENSEE agrees to use the MATERIAL in compliance with all applicable statutes and regulations including, for example, those relating to research involving the use of animals or recombinant DNA.
Amendment 2
Page 18 of 35

11.    UNIVERSITY agrees to use the Modifications in compliance with all applicable statutes and regulations including, for example, those relating to research involving the use of animals or recombinant DNA.
12.    In consideration of the grant in Paragraph 2 above, LICENSEE agrees to grant back to UNIVERSITY half of the material of Modifications assembled by LICENSEE. UNIVERSITY shall be allowed to use such material in accordance with Art. 13 of this Amendment.
13.    UNIVERSITY reserves the right to
(a)  use the MATERIAL, Modifications and Binders prepared by UNIVERSITY far educational and research purposes free of charge;
(b)  publish or otherwise disseminate any information on the MATERIAL, Modifications and Binders prepared by UNIVERSITY at any time:
(c)  use Modifications in collaborative research projects with non-commercial third parties, provided that such projects shall be governed by collaborative research agreements between UNIVERSITY and the third party comprising a detailed research plan;
(d)  and allow other nonprofit institutions to use the MATERIAL, Modifications and Binders prepared by UNIVERSITY for educational and non-commercial research purposes in their facilities free of charge, provided that Modifications shall be transferred to third non-commercial parties only if UNIVERSITY concludes in good faith that such transfer is essential for a collaborative research project and only under the following provisions:
[***]
14.    All terms and conditions of the License Agreement and its Amendment No. 1 shall remain in full force and effect.
15.    This Amendment shall be effective retroactively as of November 17,2004.
* * * * * * * *
Amendment 2
Page 19 of 35

												
	For LICENSEE
		
				
	Date:			
				
	By:			
		(Printed Name and Title/Position)
		(Signature)
				
	Date:			
				
	By:			
		(Printed Name and Title/Position)
		(Signature)
				
	For UNIVERSITY
		
				
	Date:			
				
	By:			
				(Signature)
	Date:			
				
	By:			
				(Signature)

Amendment 2
Page 20 of 35

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Amendment No. 3 dated November 15, 2005, to the License Agreement 
between
The University of Zurich, Rämistrasse 71, CH-8006 Zürich (“UNIVERSITY”) and
Molecular Partners AG, c/o Dept. of Biochemistry, University of Zurich, Winterthurerstr. 190. CH-8057 Zürich (“LICENSEE”).
WHEREAS
a. UNIVERSITY and LICENSEE have entered into a License Agreement, effective November 17, 2004, on “collections of (poly)peptides/proteins based on repeat modules (the “License Agreement”);
b. The parties wish to amend the License Agreement in order to specify Art. 2.4 of the License Agreement on the transfer of biological material that is relevant to practice the granted rights from UNIVERSITY to LICENSEE.
NOW, IT IS AGREED AS FOLLOWS:
1.Definitions:
“Original Material” shall mean the following biological materials: 
[***]
“MATERIAL” shall mean Original Material and Progeny and Unmodified Derivatives thereof.
“Progeny” shall mean unmodified descendant from the MATERIAL, such as virus from virus, cell from cell, or organism from organism.
“Unmodified Derivatives” shall mean substances created by LICENSEE which constitute an unmodified functional subunit of the Original Biological Material or a product expressed by the Original Biological Material.
“Modifications” shall mean substances created by LICENSEE which contain/incorporate the MATERIAL.
“Licensed Field of Use” shall mean therapeutic use, diagnostic use and biotechnological use.
2.UNIVERSITY hereby grants to LICENSEE a worldwide, license to commercially exploit the MATERIAL in the Licensed Field of Use. Such license shall be exclusive for the biological material defined under Group A above and non-exclusive for the biological material defined under Group B above.
3. UNIVERSITY retains ownership of the MATERIAL.
(a)Modifications shall be owned by LICENSEE.
Amendment 3
Page 21 of 35

4.(a) In consideration of the grant in Paragraph 2 above, LICENSEE hereby agrees that the financial terms set forth in Art. 3 of the License Agreement shall apply to any commercial use or sale of the MATERIAL or Modifications that fall under the definition of Licensed Product as set forth in the License Agreement. The fees and royalties due for the commercial use of such MATERIAL or Modifications are not cumulative with those of the License Agreement.
(b) For any MATERIAL, or Modifications which does not fall under the definition of Licensed Product as set forth in the License Agreement: LICENSEE shall pay a reduced rate of [***] of what would be due to UNIVERSITY if such MATERIAL or Modification would constitute a Licensed Product. Payments under this Paragraph 4(b) shall only be due for the [***] after execution of this Amendment.
5.Any MATERIAL delivered pursuant to this Amendment is understood to be experimental in nature and may have hazardous properties. UNIVERSITY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.
6.Any Modifications delivered pursuant to this Amendment is understood to be experimental in nature and may have hazardous properties. LICENSEE MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE Modifications WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.
7.Except to the extent prohibited by law, LICENSEE assumes all liability for damages that may arise from its use, storage or disposal of the MATERIAL. UNIVERSITY will not be liable to LICENSEE for any loss, claim or demand made by LICENSEE, or made against LICENSEE by any other party, due to or arising from the use of the MATERIAL by LICENSEE.
8.Except to the extent prohibited by law, UNIVERSITY assumes all liability for damages that may arise from its use, storage or disposal of the Modifications. LICENSEE will not be liable to UNIVERSITY for any loss, claim or demand made by UNIVERSITY, or made against UNIVERSITY by any other party, due to or arising from the use of the Modifications by UNIVERSITY.
9.For the use of MATERIAL and Modifications the parties agree to provide appropriate acknowledgment of the source of the MATERIAL or Modification in all publications.
10.LICENSEE agrees to use the MATERIAL in compliance with all applicable statutes and regulations including, for example, those relating to research involving the use of animals or recombinant DNA.
11.UNIVERSITY agrees to use the Modifications in compliance with all applicable statutes and regulations including, for example, those relating to research involving the use of animals or recombinant DNA.
Amendment 3
Page 22 of 35

12.In recognition of the rights granted by UNIVERSITY to LICENSEE by this Agreement, LICENSEE agrees to provide samples of Modifications to UNIVERSITY until [***], unless such transfer is not possible because a third party claims rights in such Modifications or parts thereof. UNIVERSITY shall have the right to use such samples in accordance with the following provisions:
(a)use for educational and research purposes internally and in collaborative research projects with non-commercial third parties;
(b)allow other nonprofit institutions to use the samples for educational and noncommercial research purposes in their facilities free of charge, provided that they shall be transferred to third non-commercial parties only if UNIVERSITY concludes in good faith that such transfer is essential for a collaborative research project and only under the provision that the third party will only be allowed to use the samples to carry out its tasks in the collaboration and not for any further use.
13.UNIVERSITY reserves the right to
(a)use the MATERIAL for educational and research purposes free of charge;
(b)publish or otherwise disseminate any information on the MATERIAL at any time;
(c)and allow other nonprofit institutions to use the MATERIAL for educational and noncommercial research purposes in their facilities free of charge.
14.All terms and conditions of the License Agreement and its Amendments No. 1 and 2 shall remain in full force and effect.
15.This Amendment shall be effective retroactively as of November 17, 2004.
* * * * *  * * * * *
Amendment 3
Page 23 of 35

												
	For LICENSEE
		
				
	Date:			
				
	By:			
		(Printed Name and Title/Position)
		(Signature)
				
	Date:			
				
	By:			
		(Printed Name and Title/Position)
		(Signature)
				
	For UNIVERSITY
		
				
	Date:			
				
	By:	Prof. Andreas Plückthun		
				(Signature)
	Date:			
				
	By:	Prof. Alexander Borbély		
				(Signature)

Amendment 3
Page 24 of 35

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Amendment No. 4 dated May 31st, 2007, to the License Agreement between
The University of Zurich, Ramistrasse 71, 8006 Zurich (“UNIVERSITY”)
and
Molecular Partners AG, Grabenstrasse 11a, 8952 Zurich-Schlieren (“LICENSEE”).
WHEREAS
a.    UNIVERSITY and LICENSEE have entered into a License Agreement, effective November 17, 2004, on Patent Rights in the field of collections of (poly)peptides/proteins based on repeat modules (the “Agreement”);
b.    The parties wish to amend the Agreement.
NOW, IT IS AGREED AS FOLLOWS:
1.Clause No. 3.1.(a) shall be replaced by the following:
In recognition of LICENSEE being a startup business and partially in lieu of cash, a license issue fee in the form of [***] shares with a nominal value of CHF [***] of LICENSEE’s common stock representing [***]% of the LICENSEE’s total authorized equity capital of CHF [***]. The stock or if stocks are not issued physically a copy of the updated share register shall be delivered to UNIVERSITY within [***] of execution of this Agreement. In the event of a capital increase the UNIVERSITY’s equity position may be diluted, however such dilution shall in no event be greater than that of [***] and furthermore UNIVERSITY’s equity position shall not be diluted below [***]% of the total outstanding stock of LICENSEE until LICENSEE has accrued total funds of CHF [***] in form of equity capital (valued on the basis of valuations underlying arm’s length and bona fide capital increases and/or share transfers in accordance with the LICENSEE’S shareholders agreement). Shares issued to University shall provide as far as applicable for equal but proportionate rights and restrictions as the Founder’s shares. UNIVERSITY shall adhere to the LICENSEE’S shareholders agreement and such other agreements as may be required or amended from time to time to give effect to this paragraph. The Founders of the LICENSEE are Patrick Amstutz, Hans Kaspar Binz, Patrik Forrer, Martin Alexander Kawe, Andreas Pluckthun, Michael Tobias Stumpp and Christian Zahnd.
2.Clause No. 3.1.(c) shall be replaced by the following:
On all sublicense fees received by LICENSEE from each Sublicensee that are not earned royalties:
-    [***] on fraction < [***] CHF for particular sublicense by particular Sublicensee
-    [***] on fraction>= [***] CHF and< [***] CHF for particular sublicense by particular Sublicensee
-    [***] on fraction>= [***] CHF and< [***] CHF for particular sublicense by particular Sublicensee
-    [***] on fraction >= [***] CHF and < [***] CHF for particular sublicense by particular Sublicensee
-    [***] on fraction>= [***] CHF for particular sublicense by particular Sublicensee 
It is understood that payments from Sublicensees to LICENSEE dedicated for direct use for the financing of research or product development under a joint research or development agreement 
Amendment 4
Page 25 of 35

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

shall not be considered sublicense fees and no compensation for UNIVERSITY shall be due on such payments.
3.The Agreement shall be amended with a Clause No. 3.1 (f) reading as follows:
LICENSEE shall pay UNIVERSITY an annual minimum payment on or before November 17 of each year as follows:
- 2007 and 2008: CHF [***].- each year
 - 2009 and 2010: CHF [***].- each year 
- as from 2011 each year: CHF 50’000.-
Any payments due to UNIVERSITY in the same calendar year in accordance with clauses 3.1 (b), (c) and (d) shall be deductible from such annual minimum payments.
4.Clause No. 9 (“Use of Names and Trademarks”) shall be replaced to read:
ARTICLE 9. USE OF NAMES AND TRADEMARKS AND DISCLOSURE OF THIS AGREEMENT
9.1    Nothing contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing).
9.2    UNIVERSITY may disclose to the inventors the terms and conditions of this Agreement upon their request. If such disclosure is made, UNIVERSITY shall request the Inventors not to disclose such terms and conditions to others.
9.3    UNIVERSITY may acknowledge the existence of this Agreement and the extent of the grant in Article 2 to third parties, but UNIVERSITY shall not disclose the financial terms of this Agreement to third parties, except where UNIVERSITY is required by law to do so.
9.4    LICENSEE may disclose to potential investors the terms and conditions of this Agreement. If such disclosure is made, LICENSEE shall request the potential investors to keep such information confidential and not to disclose such terms and conditions to third parties.
9.5    LICENSEE may acknowledge the existence of this Agreement and the extent of the grant in Article 2 to third parties, but LICENSEE shall not disclose the financial terms of this Agreement to third parties, except as stated in Article 9.4 or where LICENSEE is required by law to do so.
5.Clause No. 10.2 (“Assignability”) shall be replaced to read:
Assignability. This Agreement shall not be assigned by LICENSEE except:
(a)    with the prior written consent of UNIVERSITY, which consent shall not be unreasonably withheld or delayed; or
(b)    without UNIVERSITY’s consent if assigned as part of a sale or transfer of all or substantially all of the assets or the business of LICENSEE relating to operations which concern this Agreement.
6.All other terms and conditions of the Agreement shall remain in full force and effect.
Amendment 4
Page 26 of 35

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

7.This Amendment shall be effective retroactively as of January 1, 2007.
**********
Amendment 4
Page 27 of 35

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

												
	For LICENSEE (Molecular Partners AG)
		
				
	Date:			
				
	By:			
		(Printed Name and Title/Position)
		(Signature)
				
	Date:			
				
	By:			
		(Printed Name and Title/Position)
		(Signature)
				
	For UNIVERSITY
		
				
	Date:			
				
	By:	Peter Bless		
		Director of Administration		(Signature)
				
	Date:			
				
	By:	Prof. Heini Murer		
		Vice President		(Signature)

Amendment 4
Page 28 of 35

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Amendment No. 5 dated October 3, 2007, to the License Agreement
between
The University of Zurich, Rämistrasse 71, CH-8006 Zürich ("UNIVERSITY")
and
Molecular Partners AG, Grabenstrasse 11a, CH-8952 Zürich-Schlieren ("LICENSEE").
WHEREAS
a.    UNIVERSITY and LICENSEE have entered into a License Agreement, effective November 17, 2004, on "collections of (poly)peptides/proteins based on repeat modules (the "License Agreement");
b.    The parties have collaborated in the CTI-Project No. 7505.1 DCS-LS, "Designed Repeat Proteins: Novel Receptor Molecules for Life Science, Diagnostics and Therapy" and on April 26, 2006, have executed a contract governing such CTI-Project (the "CTI-Project Contract")
c.    LICENSEE wishes to license patent rights owned by UNIVERSITY and developed in the course of the CTI-Project and UNIVERSITY agrees to license these patent rights to LICENSEE, as set forth in the CTI-Project Contract, at the terms and conditions of the License Agreement; it is understood that the fees and royalties due for commercial use of such further patent rights are not cumulative with those of the License Agreement;
d.    The parties wish to amend the License Agreement accordingly.
NOW, IT IS AGREED AS FOLLOWS:
1.    Annex 1 of the License Agreement ("List of Patent Rights") shall be amended as follows:
[***]
2.    All terms and conditions of the License Agreement shall remain in full force and effect.
3.    This Amendment shall be effective retroactively as of September 24, 2007.
********
Amendment 5
Page 29 of 35

												
	For LICENSEE
		
				
	Date:			
				
	By:			
		(Printed Name and Title/Position)
		(Signature)
				
	Date:			
				
	By:			
		(Printed Name and Title/Position)
		(Signature)
				
	For UNIVERSITY
		
				
	Date:			
				
	By:	Prof. A. Plückthun		
				(Signature)
				
	Date:			
				
	By:	Prof. H Murer		
		Prorektor MNW		(Signature)

Amendment 5
Page 30 of 35

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Amendment No. 6 dated June 15, 2012, to the License Agreement
between
The University of Zurich, Rämistrasse 71, CH-8006 Zürich ("UNIVERSITY")
and
Molecular Partners AG, Grabenstrasse 11a, CH-8952 Zürich-Schlieren ("LICENSEE").
WHEREAS
a.    UNIVERSITY and LICENSEE have entered into a License Agreement, effective November 17, 2004, on "collections of (poly) peptides/proteins based on repeat modules (the "License Agreement");
b.    The parties wish to amend the License Agreement in order to clarify section 3.1.(c)
NOW, IT IS AGREED AS FOLLOWS:
1.    Clause No. 3.1.(c) of the License Agreement shall be replaced by the following:
On all Net Sublicense Fees received by LICENSEE from each Sublicensee that are not earned royalties:
- [***] on fraction < [***] CHF for particular sublicense agreement by particular Sublicensee
- [***] on fraction >= [***] CHF and < [***] CHF for particular sublicense agreement by particular Sublicensee
- [***] on fraction >= [***] CHF and < [***] CHF for particular sublicense agreement by particular Sublicensee
- [***] on fraction >= [***] CHF and < [***] CHF for particular sublicense agreement by particular Sublicensee
- [***] on fraction >= [***] CHF for particular sublicense agreement by particular Sublicensee
Net Sublicense Fees shall be total sublicense fees received by LICENSEE under a particular sublicense agreement less the sum of the following out of pocket costs actually paid to third parties and directly related to such sublicense agreements as evidenced by respective invoices. i) costs of consultants negotiating the respective sublicense agreement on behalf of LICENSEE and ii) costs of legal counseling.
It is understood that payments from Sublicensees to LICENSEE dedicated for direct use for the financing of future research or product development under a joint research or development agreement shall not be considered sublicense fees and no compensation for UNIVERSITY shall be due on such payments.
2.    All terms and conditions of the License Agreement shall remain in full force and effect.

Amendment 6
Page 31 of 35

3.    This Amendment shall be effective as of June 15, 2012. It is agreed that out of pocket costs accrued before the effective date of this Amendment shall not be deductible from sublicense fees.
********
Amendment 6
Page 32 of 35

												
	For LICENSEE
		
				
	Date:			
				
	By:			
		(Printed Name and Title/Position)
		(Signature)
				
	Date:			
				
	By:			
		(Printed Name and Title/Position)
		(Signature)
				
	For UNIVERSITY
		
				
	Date:			
				
	By:	Prof. Dr. Daniel Wyler		
		Vice President		(Signature)
				
	Date:			
				
	By:	Stefan Schnyder		
		Director Finance, HR & Infrastructure		(Signature)

Amendment 6
Page 33 of 35

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Amendment No. 7
to the License Agreement dated November 17, 2004
between
The University of Zurich, having a business address at Rämistrasse 71, 8006 Zürich, Switzerland (hereinafter referred to as University) on the one part 
and
Molecular Partners AG, having a business address at Wagistrasse 14, 8952 Schlieren, Switzerland (hereinafter referred to as Licensee) on the other part.
(University and Licensee hereinafter individually referred to as Party collectively as Parties.)
WHEREAS, University and Licensee concluded on November 17, 2004 a License Agreement, as amended by an Amendment No. 1 dated November 15, 2005 (the Amendment 1), by an Amendment No. 2 dated November 15, 2005 (the Amendment 2), by an Amendment No. 3 dated November 15, 2005 (the Amendment 3), by an Amendment No. 4 dated May 31st, 2007 (the Amendment 4), by an Amendment No. 5 dated October 3, 2007 (the Amendment 5) and by an Amendment No. 6 dated June 15, 2012 (the Amendment 6) (together, the Agreement);

WHEREAS by means of the present amendment (the Amendment 7), the Parties intend to remove from the list of Patent Rights under the Agreement (i) [***] and (ii) [***]; and 
WHEREAS, unless otherwise specified, capitalized terms shall have the meaning as set forth in the Agreement.
NOW THEREFORE; the Parties agree as follows:
1.The following Patent Rights shall be removed from the list of Patent Rights (Annex A) under the Agreement: (i) [***] and (ii) [***]. Therefore, Annex A of the Agreement shall be amended and replaced as follows:

List of Patent Rights

[***]
2.Amendment 1 and Amendment 5 of the Agreement shall be cancelled herewith. The Patent Rights licensed by University to Licensee under Amendment 1 [***] will continue to be licensed to Licensee under a separate license agreement to be entered into by the Parties concurrently herewith.
3.As a prerequisite for University to enter into this Amendment 7 Licensee represents and warrants that the Patent Rights licensed by University to Licensee under Amendment 1 [***] have not been used to develop or produce products of Licensee which are in preclinical or clinical development, particularly not for Licensee's products [***].
Amendment 7
Page 34 of 35

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

4.The Amendment 7 shall enter into force on November 15, 2019 (the Amendment 7 Effective Date).
5.Except as expressly amended herein, the Agreement shall remain in full force and effect.

IN WITNESS WHEREOF, the Parties have executed this Amendment by their duly authorised representatives as of the Amendment Effective Date.

									
	Molecular Partners AG		The University of Zurich

			
			
	Print name: 		Print name: Prof. Dr. Michael Schaepman
	Title: 		Title: Vice President Research
	Date:		Date:
			
			
	Print name: 		Print name: Stefan Schnyder
	Title: 		Title: Director Finances & HR
	Date:		Date:

Amendment 7
Page 35 of 35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]